Buy or sell Codiak Biosciences stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Codiak Biosciences Stock
Biotechnology
About Codiak Biosciences Stock
Codiak Biosciences is developing exosomes, natural vesicles that mediate inter-cellular communication, as both a powerful therapeutic modality and an advanced diagnostic system. Codiak is building a world-class team and has generated and acquired foundational intellectual property that will allow it to capitalize on the unique potential of exosome biology.
Investors
Alaska Permanent Fund
Alexandria Venture Investments
ARCH Venture Partners
Grail, Aledade, Codiak Biosciences, Mindstrong, Metacrine, Beam Therapeutics
Boxer Capital
Casdin Capital
23andMe, Genapsys, ORIC Pharmaceuticals, Codiak Biosciences, Vineti, Komodo Health
EcoR1 Capital
Flagship Pioneering
Indigo, Codiak Biosciences, Rubius Therapeutics, Cygnal Therapeutics
Qatar Investment Authority
Flipkart, SoFi, Eat Just, Thumbtack, impact.com, D2iQ, Codiak Biosciences
Sirona Capital
Yukon Partners
Funding History
| November 2015 | $33.2M |
|---|---|
| November 2015 | $64.2M |
| November 2017 | $76.5M |
Management
Chief Executive Officer
Doug Williams
Chief Business Officer
Richard Brudnick
Chief Financial Officer
Linda C. Bain
Scientific Co-Founder
Raghu Kalluri
Scientific Co-Founder
Eric Lander
Chief Scientist
Jan Lötvall
Press
PR Newswire (press release) - Jun, 4 2018
Business Wire (press release) - Dec, 21 2017
PR Newswire (press release) - Nov, 29 2017
BioSpace - May, 1 2019
exomes - Apr, 30 2019
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
